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1. Introduction 
Autologous bone is generally considered the gold-standard graft material. The advantage of 
an autograft is that it contains viable osteoblasts and osteogenic precursor cells that can 
contribute to the formation of new bone (Arrington et al, 1996). In addition, the autograft 
possesses the three essential elements of bone regeneration -osteogenesis, osteoinduction, 
and osteoconduction- that are required for bone regeneration. However, only a minimal 
amount of bone tissue can be harvested for autografts, the harvesting procedure may lead to 
donor site discomfort and morbidity, and it may be difficult to form this tissue into the 
desired shape (Goldberg & Stevenson, 1987; Damien & Parsons, 1991), a problem that is 
particularly important in the craniofacial region.  
Therefore, bone graft substitutes have been used to reconstruct bone defects. A bone graft 
substitute should be osteoconductive, osteoinductive, biocompatible, biodegradable, 
structurally similar to bone, easy to use, and cost-effective (Giannoudis et al, 2005). 
Hydroxyapatite (HA) and β-tricalcium phosphate (β-TCP) are both well-known ceramics 
that possess high tissue compatibility and osteoconductivity. However, neither HA nor β-
TCP has osteoinductive or osteogenic abilities, and HA usually shows minimal 
biodegradation (Spector, 1994;  Schmitz et al, 1999). 
To overcome these limitations, bone tissue engineering has been promoted as a new way to 
regenerate bone tissue. This approach combines cells capable of osteogenic activity and 
osteoinductive signal molecules with an appropriate material (Livingston et al, 2005). For 
bone tissue engineering to succeed, osteoconductive scaffolding biomaterials must provide a 
suitable environment for the cells. Furthermore, it is desirable that the scaffolds can control 
the release of growth factors. Accordingly, functional composite scaffolds for bone tissue 
engineering have been developed in combination with synthetic ceramics and natural 
polymers. 
Recently, minimally invasive treatments have been developed using an injectable system for 
bone tissue engineering. Several injectable gels have been used to carry cells in order to 
engineer bone. Amongst which are collagen (Tsuchida et al, 2003), alginate (Shang et al, 
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2001; Wang et al 2003), and fibrin (Perka et al 2001) gels, but these substances cannot be 
molded to the shapes of the bone defects when injected in situ or that they cannot follow the 
shapes of 3D cell culture molds in vitro.  
In this chapter, I introduce the design of injectable composite scaffold fabricated from β-TCP 
beads and alginate for bone tissue engineering (Matsuno, 2008). The β-TCP bead/alginate 
composite is not only injectable, but also instantaneously formed from β-TCP beads and 
alginate. Therefore, the composite is sufficiently adaptable to the irregularities of bone 
defects and which possessed adequate mechanical strength. Additionally, the composite act 
as an appropriate 3D scaffold for osteogenic cells, and function as drug delivery carrier of 
growth factors. 
 
2. Preparation of injectable composite scaffold 
2.1 β-TCP beads 
β-tricalcium phosphateis a synthetic calcium phosphate ceramic used as an alternative 
autologous bone graft. It has been reported that β-TCP has good biodegradability and 
osteoconductivity as a scaffold material for bone tissue engineering (Le geros, 2002; 
Matsuno et al, 2006).  With regard to shape availability, both block and granular forms are 
available. However, both shapes pose an injectability problem and are difficult to be molded 
into a 3D structure. 
Thus, we used the β-TCP beads for injectable bone substitute. β-TCP beads were prepared in 
a manner similar to a previously described method (Ushida et al, 2001; Furukawa et al , 
2004; Miyauchi et al , 2004). An aqueous slurry of β-TCP powder (Advance Ltd., Saitama, 
Japan) and polyvinyl alcohol (Shin-Etsu Chemical Co. Ltd., Tokyo, Japan) aqueous solution 
as a binder reagent were mixed using an ultrasonic homogenizer. The resultant slurry was 
added drop-by-drop to liquid nitrogen, whereby slurry drops were frozen, and the frozen 
beads were freeze-dried. The beads were then sintered at 1100°C for 10 hours. Diameter of 
the beads was controlled at 100－1,000 μm by regulating the opening and shutting times of 
an electromagnetic valve.  
Figure 1 shows the SEM photographs of β-TCP bead and the surface of the bead. Diameter 
of the bead was about 500 μm, and micropores were observed on the surface.  
 
 
 
 
 
 
 
  
 
 
 
 
 
Fig. 1.  SEM photographs of a β-TCP bead (A) and the surface of the bead (B). 
 
 
Figure 2 shows the XRD patterns of the synthesized β-TCP beads and commercially 
available β-TCP (OSferion®; Olympus, Tokyo, Japan). There were no significant differences 
in the intensity of β-TCP peaks between β-TCP beads and commercially available β-TCP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  X-ray diffraction patterns of β-TCP beads and  commercially available β-TCP 
 
2.2 Alginate hydrogel 
Alginate has many uses in bioengineering, such as in polymer films, cell encapsulation, 
wound dressings, and surgical sponges (De Vos et al, 1997; Matthew et al, 1997). Alginic 
acid is soluble in water and can be ionically crosslinked with a non-toxic divalent cation 
solution, such as calcium chloride (De Vos et al, 1997). The calcium ions bind the guluronic 
acid sites of alginate strands together to form a stable alginate gel (Becker et al, 2001). 
However, alginate lacks the initial mechanical strength needed for bone tissue engineering.  
Alginate hydrogel was made by dissolving alginic acid sodium (Protanal LF 10/60, FMC 
BioPolymer, PA, USA) in phosphate-buffer saline (PBS) to give two final concentrations of 
1.0 and 2.0 wt％. 
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2.3 Injectable 3D-formed composite scaffold 
The β-TCP beads, with a diameter of 710－850 μm, were dipped in 1.0％ CaCl2 solution 
(Sigma-Aldrich Co.) and then dried. β-TCP beads in the syringe were sterilized with 
ethylenoxide gas and alginate hydrogel with Stericup® (0.22 μm; Millipore Co., MA, USA). 
As alginate hydrogel was pushed out from the tip of the syringe, it passed through the 
CaCl2- treated β-TCP beads. As soon as a 3D-formed composite of β-TCP beads and alginate 
was obtained due to the instantaneous crosslinking that occurred in the syringe. 
Figure 3 shows a photograph of injectable 3Dformed composite of β-TCP beads and alginate 
and a light microscope photograph of the composite. Each bead was wrapped in the 
anastomosing network of the alginate gel, and the beads were bonded tightly to form a 3D 
structure. Minute crystal projections were observed on the cross-sectional surface of the β-
TCP beads treated with CaCl2 (Fig. 4). 
 
 Fig. 3.  Injectable 3D-formed composite          Figure. 4  SEM of the surface of the 
composite.         β-TCP beads (#), alginate (+) 
 
3. Evaluation of β-TCP bead/alginate composite  
3.1 Mechanical strength of the composite 
The compression tests were performed in the two types of composites (1.0 and 2.0 wt％ 
alginate hydrogels; 5.0 mm in diameter and 10.0 mm in length). The compressive strength 
increased with increased alginate concentration. The composite of 2.0 wt％  alginate 
concentration exhibited a compressive strength of 69.0±4.6 kPa, which was significantly 
greater (P<0.05) than the strength seen with 1.0 wt％ (6.11±2.28 kPa).  
3.2 In vitro evaluation of 3D mesenchymal stem cell culture  
Human mesenchymal stem cells (MSCs) were dispersed into the alginate hydrogel. 
Following which, MSC loaded alginate hydrogel was added into the syringe which was 
packed with CaCl2-treated beads. Consequently, MSC-loaded alginate was crosslinked and 
MSCs were loaded into the 3D scaffold at about 2×105 cells/scaffold. They were cultured in 
an osteogenic differentiation medium (10mM β-glycerophosphate, 100 nM dexamethasone, 
and 50 μg/ml ascorbic acid) for 1, 7, and 14 days. 
 
Figure 5 shows the SEM photographs of MSC-loaded composite after 1 day and 14 days in 
the osteogenic differentiation culture. MSCs were observed in the composite at day 1 (Fig. 
5A). After 14 days, many calcified nodules appeared on the surface of β-TCP beads and 
alginate (Fig. 5B). 
Fig. 5. SEM of MSC-loaded composite at day 1 (A) and day 14 (B) in osteogenic 
differentiation culture. MSCs (arrow), calcified nodules (>) 
 
Figure 6 shows that the ALP activity of MSCs grown within the composite of osteogenic 
differentiation culture increased from day 1 to day 7, but decreased from day 7 to day 14. 
There was a significant increase between day 1 and day 7(*P<0.05), and similarly a 
significant decrease between day 7 and day 14 (**P<0.05). 
No OCN mRNA expression was detected at day 1. However, OCN mRNA expression 
increased from day 1 to day 7, and increase between day 7 and day 14 was statistically 
significant (*P<0.05) (Fig. 7). 
 
 Fig. 6. ALP activity of MSCs grown within the composite in osteogenic differentiation 
culture. 
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 Fig. 7. OCN mRNA expression levels of MSCs grown within the composite in osteogenetic 
differentiation culture.  
 
3.3 In vivo evaluation of MSCs loaded composite scaffold 
Non-osteogenic-differentiated MSCs loaded into the 3D composite scaffold (5×106 
cells/scaffold) and MSC-free composite as control were subcutaneously implanted into the 
backs of 6-week-old KSN nude mice. The mice were killed at 8 weeks after implantation.  
Figure 8 shows the histological sections of the 3D composite scaffold loaded with non-
osteogenicdifferentiated MSCs at 8 weeks after implantation. Newly formed, bone-like 
calcified tissue was directly deposited on the surface of the β-TCP beads. Interconnected 
alginate was completely degraded, and bone-like calcified tissue was observed in the 
connective tissue. The surface of the β-TCP beads was slightly degraded and vacuolization 
was observed in the beads. On the other hand, cell-free composite contained only 
fibrovascular tissue around nondegraded β-TCP beads (data was not shown). 
 Fig. 8.  HE-stained histological sections of  the composite scaffold loaded with MSCs at 8 
weeks after implantation. 
Newly formed, bone-like calcified tissue (‡), β-TCP beads (#)  
 
 
3.4 In vitro release of growth factor from composite 
A solution of basic fibroblast growth factor (bFGF) was dispersed into the alginate hydrogel. 
Following which, bFGF incorporated alginate hydrogel was added into the syringe which 
was packed with CaCl2-treated beads. Consequently, bFGF-incorporated composite scaffold 
was obtained. In vitro release tests were performed as follows. The composite scaffolds 
completely sank in the Hank’s balanced solution, and incubated at 37°CbFGF 
concentration was determined using ELISA.   
Figure 9 shows that the release of bFGF from the composite. There was a significant increase 
between day 1 and day 4 (*P<0.05). 
 Fig. 9. The release of bFGF from the composite. 
 
4. Conclusion 
Both ceramics and polymers have their own merits and drawbacks, and a better solution 
may be to synergize the advantageous properties of both materials for composite scaffolds. 
Therefore, many different composite forms such as sponges, gels, films, and blocks have 
been developed using different methods (Wahl & Czernuszka, 2006). However, multi 
functional composite such as our developed composite are little or no. 
Recently, the increasing popularity of minimally invasive techniques has led to the 
development of an injectable system that can be molded to the shape of the bone defect and 
which polymerizes when injected into the site (Niemeyer et al, 2004). Such devices should be 
easy to implant, thereby shortening the surgical time and minimizing the damage to healthy 
tissue. β-TCP has been used for bone tissue engineering. However, it is difficult to fit into 
the surgical sites around implants or to be shaped to the desired forms using β-TCP blocks 
or granules. The composites consisting of β-TCP beads and alginate can be injects into bone 
defect site. On the other hand, the composite can simply be cut with scissors or a sharp 
knife, and can therefore be easily molded for use for various tissue disorders.  
Bone tissue engineering approach is to combine osteogenetic cells with an appropriate 
composite scaffold. In keeping with the tissue engineering concept, cells are cultivated on an 
appropriate 3D scaffolds to replace 3D tissue defects (Liu et al, 2006). However, elaborate 
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seeding and culture conditions are needed to achieve uniform cellular distribution, sustain 
cell viability, and provide nutrients for tissue formation in scaffolds (Weinand et al, 2006). 
In this study, alginate hydrogel was used to facilitate the delivery and distribution of MSCs. 
It has been previously demonstrated that alginate hydrogels induce bone formation in vitro 
(Weinand et al, 2006; Alsberg et al, 2001). However, the lack of adequate initial strength of 
hydrogel/cell constructs requires additional mechanical support for implantation 
(Niemeyer et al, 2004). Therefore, a uniform size of CaCl2-coated β-TCP beads was selected 
to reinforce the initial strength. Calcium ions can be crosslinked with the guluronic acid sites 
of alginate strands to form a stable alginate gel (Becker et al, 2001). Leveraging on all these 
properties in this study, an instantaneously formed, injectable 3D scaffold was obtained 
after alginate hydrogel reacted with CaCl2-coated β-TCP beads and then loaded with MSCs. 
In vitro evaluation, ALP activity at 7 days was significantly increased as compared to day 1, 
but decreased from day 7 to day 14. As a marker of early osteogenic differentiation, the ALP 
activity of the construct was measured on days 1, 7, and 14 of the culture period. The typical 
rise and fall of ALP activity was characteristic of osteogenic differentiation and common to 
all culture systems (Shin et al, 2004). Furthermore, OCN mRNA expression, another marker 
of osteogenic differentiation, was significantly increased at day 14 as compared to day 7. 
Therefore, it is conceivable that calcification progressed in the composite. 
In vivo experiment demonstrated that the β-TCP bead/alginate composite had an 
osteoinductive effect in soft tissue ― without an osteogenic differentiation medium for 
MSCs. Similarly, Livingston et al. (2005) demonstrated that hydroxyapatite/β-TCP ceramic 
scaffold promoted bone formation in soft tissue, which was induced by non-osteogenic-
differentiated MSCs. Furthermore, this study demonstrated that β-TCP bead/alginate 
composite induced the formation of bone-like calcified tissue. Taken together, these results 
suggested that a 3D structure consisting of β-TCP beads and alginate allowed an 
appropriate spatial arrangement of osteogenic cells as well as vascular invasion. These 
findings also indicated that injectable β-TCP bead/alginate composites supported bone 
regeneration with a minimally invasive technique. 
In addition, the β-TCP bead/alginate composite can locally release growth factors from the 
composite, used as drug delivery carriers. It will be enhance bone formation to treat bone 
defects.
In light of the encouraging results obtained for osteogenesis, the novel composite developed 
in this study may be useful as an injectable scaffold for bone tissue engineering.  
 
5. References 
Alsberg, E.; Anderson, KW.; Albeiruti, A.; Franceschi, RT. & Moony, DJ.(2001). Cell-
interactive alginate hydrogels for bone tissue engineering. J Dent Res, 80, 2025-2029,  
0022-0345 
Arrington, ED.; Smith, WJ.; Chambers, HG.; Bucknell, AL. & Davino, NA. (1996). 
Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res, 329., 300-
309, 0009-921X 
Becker, TA.; Kipke, DR. & Brandon, T. (2001). Calcium alginate gel: A biocompatible and 
mechanically stable polymer for endovascular embolization. J Biomed Mater Res, 54, 
76-86, 0021-9304 
 
Damien, J. & Parsons, R. (1991). Bone graft and bone graft substitutes: a review of current 
technology and applications. J Appl Biomater, 2., 187-208, 1045-4861 
De Vos, P.; De Haan, B. & Van Schilfgaarde, R. (1997). Effect of the alginate composition on 
the biocompatibility of alginate-polylysine microcapsules. Biomaterials , 18, 273-278, 
0142-9612 
Furukawa, KS.;  Miyauchi, S.; Suzuki, D.; Umezu, Y, Shinjo, T.;  Ushida, T.; Eguchi, & 
Tateishi, T. (2004). Bone tissue engineering based on bead-cell sheets composed of 
calcium phosphate beads and bone marrow cells. Mater Sci Eng C, 24, 437-440, 0928-
4931 
Giannoudis, PV.; Dinopoulos, H. & Tsiridis E. (2005). Bone substitutes: An update. Injury, 
36., 20-27, 0020-1383 
Goldberg, M. & Stevenson, S. (1987). Natural history of autografts and allografts. Clin Orthop 
Relat Res, 225., 7-16, 0009-921X 
Le Geros, RZ. (2002). Properties of osteoconductive biomaterials: calcium phosphates. Clin 
Orthop Relat Res , 395, 81-98, 0009-921X  
Liu, H.; Li, H.; Cheng, W.; Yang, Y.; Zhu, M. & Zhou, C. (2006). Novel injectable calcium 
phosphate/chitosan composites for bone substitute materials. Acta Biomater,  2,  
557-565, 1742-7061 
Livingston, AT.; Tran, T.; Mcalary, J. & Daculsi, G. (2005). A comparative study of biphasic 
calcium phosphate ceramics for human mesenchymal stem cell-induced bone 
formation. Biomaterials, 26: 3631-3638, 0142-9612 
Matsuno, T.; Nakamura, T.; Kuremoto, K.; Notazawa, S.; Nakahara, T.; Hashimoto, Y.; 
Satoh, T. & Shimizu, Y. (2006). Development of β-tricalcium phosphate/collagen 
sponge composite for bone tissue regeneration. Dent Mater J. 25, 138-144, 0287-4547 
Matsuno, T.; Hashimoto, Y.; Adachi, S.; Omata, K.; Yoshitaka, Y.; Ozeki, Y.;  Umezu, Y.; 
Tabata, Y.; Nakamura, M. & Satoh, T. (2008). Preparation of injectable 3D-formed β-
tricalcium phosphate bead/ alginate  composite for bone tissueengineering. Dent 
Mater J. 27, 827-834, 0287-4547 
Matthew, IR.; Browne, RM.; Frame, JW. & Millar, BG. (1997). Subperiosteal behavior of 
alginate and cellulose wound dressing materials. Biomaterials, 18, 707-713, 0142-
9612 
Miyauchi, S.; Furukawa, KS.; Umezu, Y.; Ozeki, Y.; Ushida, T. & Tateishi, T. (2004). Novel 
bone graft model using bead-cell sheets composed of tricalcium phosphate beads 
and bone marrow cells. Mater Sci Eng C, 24, 875-879, 0928-4931 
Niemeyer, P.; Krause, U.; Fellenberg, J.; Kasten, P.; Seckinger, A.; Ho, AD. & Simank, HG. 
(2004). Evaluation of mineralized collagen and α-tricalcium phosphate as scaffolds 
for tissue engineering of bone using human mesenchymal stem cells. Cells Tissues 
Organs, 177, 68-78, 1422-6405 
Perka, C.; Arnold, U.; Spitzer, RS. & Lindenhayn, K. (2001). The use of fibrin beads for tissue 
engineering and subsequential transplantation. Tissue Eng, 7: 359-361, 1076-3279 
Schmitz, JP.; Hollinger, JO. & Milam, SB. (1999). Reconstruction of bone using calcium 
phosphate bone cements: A critical review. J Oral Maxillofac Surg, 57: 11221126, 
0278-2391 
Shang, Q.; Wang, Z.; Liu, W.; Shi, Y.; Cui, L. & Cao Y. (2001). Tissue-engineered bone repair 
of sheep cranial defects with autologous bone marrow stromal cells. J Craniofac 
Surg, 12: 586-593, 1049-2275 
www.intechopen.com
Design of injectable bone tissue engineering  
scaffold consists of ß-tricalcium phosphate beads and alginate 305
 
seeding and culture conditions are needed to achieve uniform cellular distribution, sustain 
cell viability, and provide nutrients for tissue formation in scaffolds (Weinand et al, 2006). 
In this study, alginate hydrogel was used to facilitate the delivery and distribution of MSCs. 
It has been previously demonstrated that alginate hydrogels induce bone formation in vitro 
(Weinand et al, 2006; Alsberg et al, 2001). However, the lack of adequate initial strength of 
hydrogel/cell constructs requires additional mechanical support for implantation 
(Niemeyer et al, 2004). Therefore, a uniform size of CaCl2-coated β-TCP beads was selected 
to reinforce the initial strength. Calcium ions can be crosslinked with the guluronic acid sites 
of alginate strands to form a stable alginate gel (Becker et al, 2001). Leveraging on all these 
properties in this study, an instantaneously formed, injectable 3D scaffold was obtained 
after alginate hydrogel reacted with CaCl2-coated β-TCP beads and then loaded with MSCs. 
In vitro evaluation, ALP activity at 7 days was significantly increased as compared to day 1, 
but decreased from day 7 to day 14. As a marker of early osteogenic differentiation, the ALP 
activity of the construct was measured on days 1, 7, and 14 of the culture period. The typical 
rise and fall of ALP activity was characteristic of osteogenic differentiation and common to 
all culture systems (Shin et al, 2004). Furthermore, OCN mRNA expression, another marker 
of osteogenic differentiation, was significantly increased at day 14 as compared to day 7. 
Therefore, it is conceivable that calcification progressed in the composite. 
In vivo experiment demonstrated that the β-TCP bead/alginate composite had an 
osteoinductive effect in soft tissue ― without an osteogenic differentiation medium for 
MSCs. Similarly, Livingston et al. (2005) demonstrated that hydroxyapatite/β-TCP ceramic 
scaffold promoted bone formation in soft tissue, which was induced by non-osteogenic-
differentiated MSCs. Furthermore, this study demonstrated that β-TCP bead/alginate 
composite induced the formation of bone-like calcified tissue. Taken together, these results 
suggested that a 3D structure consisting of β-TCP beads and alginate allowed an 
appropriate spatial arrangement of osteogenic cells as well as vascular invasion. These 
findings also indicated that injectable β-TCP bead/alginate composites supported bone 
regeneration with a minimally invasive technique. 
In addition, the β-TCP bead/alginate composite can locally release growth factors from the 
composite, used as drug delivery carriers. It will be enhance bone formation to treat bone 
defects.
In light of the encouraging results obtained for osteogenesis, the novel composite developed 
in this study may be useful as an injectable scaffold for bone tissue engineering.  
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